Sunshine Biopharma, Inc.

NasdaqCM:SBFM 株式レポート

時価総額：US$5.7m

Sunshine Biopharma マネジメント

マネジメント 基準チェック /24

Sunshine Biopharma's CEO is Steve Slilaty, appointed in Oct 2009, has a tenure of 15.08 years. total yearly compensation is $640.00K, comprised of 59.1% salary and 40.9% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth $173.21. The average tenure of the management team and the board of directors is 0.8 years and 3.1 years respectively.

主要情報

Steve Slilaty

最高経営責任者

US$640.0k

報酬総額

CEO給与比率59.1%
CEO在任期間15.1yrs
CEOの所有権0.003%
経営陣の平均在職期間less than a year
取締役会の平均在任期間3.1yrs

経営陣の近況

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12
Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sunshine Biopharma acquires Nora Pharma for C$30M

Oct 20

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Aug 08
We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Sunshine Biopharma reports 1H results

Aug 04

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Apr 17

CEO報酬分析

Sunshine Biopharma の収益と比較して、Steve Slilaty の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$640kUS$378k

-US$5m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$430kUS$360k

-US$27m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$462kUS$156k

-US$12m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$227kUS$177k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$972k

Dec 31 2019US$96kUS$28k

-US$1m

Sep 30 2019n/an/a

-US$1m

Jun 30 2019n/an/a

-US$2m

Mar 31 2019n/an/a

-US$2m

Dec 31 2018US$285kUS$85k

-US$2m

Sep 30 2018n/an/a

-US$2m

Jun 30 2018n/an/a

-US$1m

Mar 31 2018n/an/a

-US$1m

Dec 31 2017US$268kUS$156k

-US$1m

報酬と市場: Steve's total compensation ($USD640.00K) is about average for companies of similar size in the US market ($USD655.65K).

報酬と収益: Steve's compensation has increased whilst the company is unprofitable.

CEO（最高経営責任者

Steve Slilaty (72 yo)

15.1yrs

在職期間

US$640,000

報酬

Dr. Steve N. Slilaty, Ph.D. is CEO & Chairman of Sunshine Biopharma, Inc. from October 15, 2009 and serves as President. Dr. Slilaty joined the Sunshine Biopharma, Inc. on October 15, 2009. He serves as th...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Steve Slilaty
Chairman15.1yrsUS$640.00k0.0031%
$ 173.2
Camille Sebaaly
CFO & Secretary15.1yrsUS$695.00k0.0030%
$ 170.4
Abderrazzak Merzouki
Chief Science Officer & Directorless than a yearUS$340.00k0.0029%
$ 167.5
Marc Beaudoin
Chief Operating Officerless than a yearデータなしデータなし
Malek Chamoun
Chief Development Officerless than a yearデータなし0.093%
$ 5.3k
Robert Ferreira
President of Sunshine Bio Investments Incno dataデータなしデータなし

0.8yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: SBFM's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

取締役

名称ポジション在職期間報酬所有権
Steve Slilaty
Chairman15.1yrsUS$640.00k0.0031%
$ 173.2
Abderrazzak Merzouki
Chief Science Officer & Director8.8yrsUS$340.00k0.0029%
$ 167.5
David Natan
Independent Director2.8yrsUS$80.00kデータなし
Rabi Kiderchah
Independent Director3.1yrsUS$80.00k0.000050%
$ 2.8
Andrew Keller
Independent Director2.8yrsUS$80.00kデータなし

3.1yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: SBFM's board of directors are considered experienced (3.1 years average tenure).